» Articles » PMID: 37111187

A Review of the Effects of Fucoxanthin on NAFLD

Overview
Journal Nutrients
Date 2023 Apr 28
PMID 37111187
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease. Fucoxanthin, a red-orange marine carotenoid, is found in natural marine seaweeds with high antioxidant activity and several other remarkable biological features. The aim of this review is to gather evidence of the positive benefits of fucoxanthin on NAFLD. Fucoxanthin provides an extensive list of physiological and biological properties, such as hepatoprotective, anti-obesity, anti-tumor, and anti-diabetes properties, in addition to antioxidant and anti-inflammatory properties. This review focuses on published research on the preventative effects of fucoxanthin on NAFLD from the perspective of human clinical trials, animal experiments , and cell investigations. Using a variety of experimental designs, including treatment dosage, experiment model, and experimental periods, the positive effects of fucoxanthin were demonstrated. Fucoxanthin's biological activities were outlined, with an emphasis on its therapeutic efficacy in NAFLD. Fucoxanthin showed beneficial effects in modulating lipid metabolism, lipogenesis, fatty acid oxidation, adipogenesis, and oxidative stress on NAFLD. A deeper comprehension of NAFLD pathogenesis is essential for the development of novel and effective therapeutic strategies.

Citing Articles

Effectiveness of Resmetirom in Reducing Cholesterol Levels in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.

Bejitual E, Awais M, Modi D, Gul U, Obeidat K, Ahmed N Cureus. 2024; 16(10):e70859.

PMID: 39493200 PMC: 11531927. DOI: 10.7759/cureus.70859.


17β-Estradiol protects female rats from bilateral oophorectomy-induced nonalcoholic fatty liver disease induced by improving linoleic acid metabolism alteration and gut microbiota disturbance.

Tian Y, Xie Y, Hong X, Guo Z, Yu Q Heliyon. 2024; 10(7):e29013.

PMID: 38601573 PMC: 11004821. DOI: 10.1016/j.heliyon.2024.e29013.


Improving Determination of Pigment Contents in Microalgae Suspension with Absorption Spectroscopy: Light Scattering Effect and Bouguer-Lambert-Beer Law.

Yeh Y, Ebbing T, Frick K, Schmid-Staiger U, Haasdonk B, Tovar G Mar Drugs. 2023; 21(12).

PMID: 38132940 PMC: 10744667. DOI: 10.3390/md21120619.

References
1.
Zou Y, Zhong L, Hu C, Sheng G . Association between the alanine aminotransferase/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study. Lipids Health Dis. 2020; 19(1):245. PMC: 7690093. DOI: 10.1186/s12944-020-01419-z. View

2.
Shih P, Shiue S, Chen C, Cheng S, Lin H, Wu L . Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin/Adiponectin Axis. Mar Drugs. 2021; 19(3). PMC: 8001566. DOI: 10.3390/md19030148. View

3.
Ha A, Kim W . The effect of fucoxanthin rich power on the lipid metabolism in rats with a high fat diet. Nutr Res Pract. 2013; 7(4):287-93. PMC: 3746163. DOI: 10.4162/nrp.2013.7.4.287. View

4.
Gammone M, DOrazio N . Anti-obesity activity of the marine carotenoid fucoxanthin. Mar Drugs. 2015; 13(4):2196-214. PMC: 4413207. DOI: 10.3390/md13042196. View

5.
Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T . Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. Clin Gastroenterol Hepatol. 2021; 20(3):e573-e582. DOI: 10.1016/j.cgh.2021.02.030. View